Research programme: cell therapy - Angiocrine Bioscience

Drug Profile

Research programme: cell therapy - Angiocrine Bioscience

Alternative Names: E-CEL PEC™; E-CEL TEC™; E-CEL UVEC™

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator Angiocrine Bioscience
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Haematological malignancies; Sickle cell anaemia; Tendon injuries

Most Recent Events

  • 15 Sep 2016 Preclinical trials in Chronic obstructive pulmonary disease in USA (Parenteral)
  • 15 Sep 2016 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 15 Sep 2016 Preclinical trials in Sickle cell anaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top